Recombinant Human CD3 delta/CD3d Fc Chimera Protein, CF

When Recombinant Human CD3 delta/CD3d Fc Chimera (Catalog # 10280-TC) is immobilized at 1.0 μg/mL, 100 μL/well, the concentration of Biotinylated Recombinant Human CD3E Fc Chimera that produces 50% of the optimal binding response is approximately 1.0-6.0 μg/mL.

2 μg/lane of Recombinant Human CD3 delta/CD3d Fc Chimera (Catalog # 10280-TC) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 45-55 kDa and 90-110 kDa, respectively.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human CD3 delta/CD3d Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human CD3 delta/CD3d Fc Chimera (Catalog # 10280-TC) is immobilized at 1.0 μg/mL, 100 μL/well, the concentration of Recombinant Human CD3E Fc Chimera Biotinylated Protein that produces 50% of the optimal binding response is approximately 1.0-6.0 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human CD3 delta/CD3d protein
  

  Human CD3 delta/CD3d (Phe22-Ala105) Accession # P04234	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: P04234
• N-terminal Sequence: Phe22
• Structure / Form: Disulfide linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 36 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 45-55 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 250 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human CD3 delta/CD3d Fc Chimera Protein, CF

• CD3 antigen, delta subunit
• CD3 delta
• CD3d antigen
• CD3d antigen, delta polypeptide (TiT3 complex)
• CD3d molecule, delta (CD3-TCR complex)
• CD3D
• CD3-DELTA
• T3DOKT3, delta chain
• T-cell receptor T3 delta chain
• T-cell surface glycoprotein CD3 delta chain

Background

CD3d, also known as CD3 delta and T3D, is a single-pass type I membrane protein. CD3 delta/CD3d is part of the T-cell receptor/CD3 complex (TCR/CD3 complex) and is involved in T-cell development and signal transduction (1). The encoded membrane protein represents the delta subunit of the CD3 complex, and along with four other CD3 subunits, binds either TCR alpha/beta or TCR gamma/delta to form the TCR/CD3 complex on the surface of T cells (2). CD3 delta/CD3d contains an 84 amino acid extracellular domain, a 21 amino acid transmembrane domain, and a 45 amino acid cytoplasmic domain. Human CD3 delta/CD3d shares 89%, 61%, and 57% sequence identity in its extracellular domain with its cynomolgus monkey, rat, and mouse homologs, respectively. CD3 delta/CD3d, like other subunit members CD3G and CD3E of the TCR-CD3 complex, contains an extracellular Ig domain and a single immunoreceptor tyrosine-based activation motif (3, 4). Defects in CD3 delta/CD3d cause severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T-/B+/NK+ SCID) which is a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels (5, 6).

1. Gil, J. et al. (2011) J. Clin. Invest. 121:3872.
2. Carson, G.R. et al. (1991) J. Biol. Chem. 266:7883.
3. Birnbaum, M.E. et al. (2014). Proc. Natl. Acad. Sci. USA. 111:17576.
4. Wucherpfennig, K. et al. (2010). Cold Spring Harb Perspect. Biol. 2:a005140.
5. Kim, S.T. et al. (2010) J. Immunol. 185:2951.
6. Holst, J. et al. (2008) Nat. Immunol. 9:658.

Bioinformatics

• Uniprot:
  • P04234()